# Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

> **NCT07010393** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 335 (estimated)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib
- **DRUG:** Selpercatinib
- **DRUG:** Pralsetinib
- **DRUG:** Lenvatinib
- **DRUG:** Larotrectinib
- **DRUG:** Anlotinib
- **DRUG:** Pembrolizumab
- **DRUG:** Sintilimab
- **DRUG:** Cabozantinib
- **DRUG:** Bemosuzumab
- **PROCEDURE:** Conversion Surgery

## Key facts

- **NCT ID:** NCT07010393
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 335 (ESTIMATED)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010393, "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07010393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*